Association of Molecular Pathology
Meet with Q2 Solutions at the 2018 AMP Conference (booth #725) and learn how our industry-leading genomic services team can help you uncover invaluable insights from your data, accelerating your molecular pathology efforts
About This EventQ2 Solutions’ deep scientific expertise in genomics, biomarkers, companion diagnostics, bioinformatics and analytics, ensures that we can meet your specific development needs, strategically tailoring our services as your product pipeline evolves.
Our experts in biomarker discovery can provide you with a better understanding of therapeutic targets, molecular signaling, drug biology and patient response. Q2 Solutions’ genomics capabilities can help enhance your study in identifying predictive biomarkers, developing and deploying diagnostics tests, and engaging the most appropriate patient populations in support of molecular pathology advancements.
Our precision medicine laboratory services span the development lifecycle. We can begin with biomarker identification programs in early development and then progressively develop candidate biomarkers into research-appropriate tests and market-ready companion diagnostics.
Schedule a meeting with our team at this year’s AMP Conference to learn how our full in-house global Anatomic Pathology (AP) services, breakthrough genomic know-how, and operational, scientific and quality excellence make us your best precision medicine partner.
We look forward to meeting you in Texas.
Director, Translational Genomics
Dr. Victor Weigman, Ph.D. is Director, Translational Genomics at Q2 Solutions, a Quintiles Quest Joint Venture, leading the group with a goal of continued facilitation of pre-clinical drug development through biomarker identification. Ongoing research revolves around the genomic profiling of solid tumors from both DNA and RNA approaches including the development of robust assays that can be leveraged as laboratory developed tests.
Dr. Weigman brings more than 10 years of biomarker discovery research with genomics, with a majority of them dedicated to Expression Analysis (EA), a Q2 Solutions Company. He has published 14 papers on biomarker identification and assay development and has contributed to the development and launch of several genomic CLIA Assays. Additionally, Dr. Weigman is involved in pharma partnerships for clinical trial development using genomic profiling technologies.
Dr. Weigman obtained his Ph.D. at the University of North Carolina in Biology and Bioinformatics within the Lineberger Comprehensive Cancer Center.
Updated as of September 2018.